Abstract
Two prior industry-sponsored, randomized, phase III trials, BOLERO-1 (Lancet Oncol 2015; 16:816) and BOLERO-3 (Lancet Oncol 2014; 15:580), explored whether the mTOR inhibitor everolimus would provide clinical benefit to patients with advanced breast cancer. In BOLERO-1, adding everolimus to trastuzumab and paclitaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive disease did not improve progression-free survival (PFS). In the BOLERO-3 trial, adding everolimus to trastuzumab and vinorelbine …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
